Latest Forum Topics / Biosensors | Post Reply |
Is Biosensors a good buy?
|
|
bengster68
Master |
03-Nov-2007 11:55
|
x 0
x 0 Alert Admin |
I don't short stocks as i think it is bad karma to incur losses to others with the hope of gaining for yourself. Very "Chek Erk" thing to do. Better don't short lah. Look for undervalued stocks, buy and hold. I think in the long run only warren buffet strategy can make money for we retail investors. For me, although this company is pre-earnings stage and Mr Buffet wouldn't invest in such a company, i minimise the risk by knowing this company thoroughly and know where this company and their competitors stand in global DES arena. Im confident BIG will be a global DES powerhouse and the returns will be a multi-bagger. If we trade fast, long/short, we are only retail players how can our insider news/ skill / disclipline/ bullets match with real syndicate BB or professional house traders? If you are good and lucky you may be making for one year but one bad month can erase all your profits and make you deep into losses. Just my opinion |
Useful To Me Not Useful To Me | |
bengster68
Master |
03-Nov-2007 11:34
|
x 1
x 0 Alert Admin |
I also waiting anxiously for LEADERS results. I think the full 9 months results will be announced in EuroPCR in May 2008. I think by then JNJ may really up their offer to above $3. JNJ can pay a lot more if Biomatrix has certainty of excellent performance in massive clinical trials. JNJ was so desperate and took risk to buy Conor before having the results of Costar RCT against Taxus. Once bitten, twice shy. Even if JNJ offer $2.50 immediately after Biomatrix CE, i think BIG's key shareholders will not sell. So to JNJ, why not wait until BIG has the full LEADERS results before they make the $3 offer? But if BIG performs very well in LEADERS (i honestly think they will), the key shareholders may want to up their price to $4 for price premium in certainty of excellent LEADERS trial. By then with Biomatrix, Xience and Endeavor creating havoc in CE standard countries plus Xience and Endeavor penetrating deeply into US market, JNJ have no other choice but to say yes? But it will still be worthwhile for JNJ because BIG has the best stent technology that will fend off newer competitors and make them the global DES king again. Abbott paid over US$4.1B for Xience (and that is before Xience's CE and SPIRIT III RCT results against Taxus). If JNJ pay US$3B for BIG, i think it is still a good deal for JNJ. Biomatrix's short-term and long-term performance is better than Xience. Xience has the dreaded late-thrombosis problem and potentially deadly drug/polymer coating spliting problem. BIG has proprietary IP, patents and future generation DES in the pipeline like Biomatrix Freedom, Fully bioabsorbable DES and the lastest China DES jewel JWMS. |
Useful To Me Not Useful To Me | |
|
|
Younglady
Member |
03-Nov-2007 11:14
|
x 0
x 0 Alert Admin |
WHo can advise whether to short see-no-star like what jackjames mention or this counter???? i agree I see no star for sinostar. haha i duno leh. what ur advise bengstar, u really are beng-star. haha. veteran, pls advise. urgent wor.thanks any and everyone. both counter seem alright but fluctuation higher for this counter |
Useful To Me Not Useful To Me | |
cwwan1
Member |
03-Nov-2007 10:20
|
x 0
x 0 Alert Admin |
Hi Ben, how is the leaders trial result after one year, this is the biggest patient trial for Biomatrix so far and why Bio is not communicating the result? |
Useful To Me Not Useful To Me | |
cwwan1
Member |
03-Nov-2007 00:48
|
x 0
x 0 Alert Admin |
Most likely the quarterly result is in the red again, hopefully not much as the all related biomatrix trial are booked in the previous quarters.... |
Useful To Me Not Useful To Me | |
|
|
787180
Master |
02-Nov-2007 23:05
|
x 0
x 0 Alert Admin |
Biosensors +8.6%; S$0.90 Resistance Tipped
[Dow Jones] Biosensors (B20.SG) +8.6% at 3-month high of S$0.88 on strong volume, extending gains for third straight day, possibly on hopes of increased market acceptance of its drug-eluting stents. Company''s stent technology showcased last week at medical convention in U.S., with results from trials showing positive performance of its stents in heart patients. Findings stirring hopes of company securing coveted CE mark. "If that''s the case, the gains would be really, really massive," says local house analyst. Resistance at S$0.90 (61.8% forward retracement to June 22 high of S$1.04 from this week''s low of S$0.685). |
Useful To Me Not Useful To Me | |
PinkyGoh
Member |
02-Nov-2007 21:09
|
x 0
x 0 Alert Admin |
starts countdown........... Biosensors to Host Global Investor Conference Call to Discuss Fiscal Year 2008 Second Quarter and First Half Financial Results Biosensors International Group, Ltd. (?Biosensors? or the ?Company?) will announce its financial results for the second quarter and first half of its fiscal year ended 30 September 2007 on Monday, 12 November 2007 before trading hours. The Company will also host a global investor conference call to discuss its financial results on Monday, 12 November 2007 at 12.30 pm, Singapore time. The call will be chaired by Mr. Yoh- Chie Lu, Chairman and CEO of Biosensors and will last for approximately 1 hour. A live webcast of the call will be available to all interested parties at Biosensors? website www.biosensors.com Company?s Investor Relations section at the call. at the stated time. A replay of the webcast will be available in thewww.biosensors.com approximately 4 hours after |
Useful To Me Not Useful To Me | |
novena_33
Veteran |
02-Nov-2007 17:52
|
x 0
x 0 Alert Admin |
no strong heart...better stay out...if not... may end up...using there product... just joking....... hopefully after all the warrant expire... the price can get stable....and then time to move on.... Cheong....BIG.... |
Useful To Me Not Useful To Me | |
|
|
left_bug
Senior |
02-Nov-2007 17:50
|
x 0
x 0 Alert Admin |
Gees, Mr. Pension, have not see you for a while. Where have you been? |
Useful To Me Not Useful To Me | |
Pension
Elite |
02-Nov-2007 17:47
|
x 0
x 0 Alert Admin |
this is a very volatile counter, trade with extreme care. |
Useful To Me Not Useful To Me | |
bengster68
Master |
02-Nov-2007 17:09
|
x 0
x 0 Alert Admin |
Sori lah Younglady, i ah beng mah, so my answer sometimes sound very beng lor. Your question: today will close at what price..... how to answer you and how to predict? Share price is even harder to predict than say... a young lady's mood? Xience V is the best efficacy DES commercially available now. Their 9 months results against Taxus is fantastic, but their performance still lose to Biomatrix. Remeber Everolimus was discarded to Guidant after BIG has found their new drug weapon: Biolimus A9. Biolimus is definitely a better drug than Everolimus. Biolimus A9 is a fat seeking drug, fat is the plaque that clogs up the arteries and that is why the stent is used to prop up the fat clogged artery. The efficacy of the drug is not wasted and dissolved in the blood stream. Biolimus will seek the fat plaque to promote a better healing progress with less scarring. Scarring can renarrow the propped up artery and in more severe renarrowing cases, totally close up the artery (very deadly)! The problem is Xience has cases of late thrombosis (blood clots) after 6 months of stent implant. I mentioned this in my previous posts over a week ago on this issue. The main focus are those blood clots after 6 months. Xience is not free from late-thrombosis, the precise problem plaguing the DES industry now. That means Xience is also may not a safe stent (just like Cypher and Taxus) although its short term performance is better than existing approved DES . Longer data (preferably with large number of patients involoved) is needed to have a better picture. I also posted here before Xience uses a thin flora non-adhesive polymer and there are cases of their Everolimus drug coating splits from the polymer coating. This is potentially very dangerous and experts have warned Abbott to stop selling Xience but money motivation is priority at the moment. My gut feel is couple of years down the road more problems will surface on Xience DES. Do not be too happy when short term result is good because a stents normally stay in patient for 10 to 20 years until the patient report to Moses. |
Useful To Me Not Useful To Me | |
787180
Master |
02-Nov-2007 16:13
|
x 0
x 0 Alert Admin |
drop on small vol..gd sign..show pple are reluctant to sell..those sold are probably the contra players |
Useful To Me Not Useful To Me | |
|
|
AK_Francis
Supreme |
02-Nov-2007 15:34
Yells: "Happy go lucky, cheers." |
x 0
x 0 Alert Admin |
So far steady lah, despite ST plunged over 100. Cross the fingers and hope for the best to come. However, tonite DJ performance is a bit pesimistic. I guess. |
Useful To Me Not Useful To Me | |
A02041315
Senior |
02-Nov-2007 15:24
|
x 0
x 0 Alert Admin |
Abbott Suffers as J&J Clot Woes, Stent Review Nears (Update2) Bro. Bengster:What is it? |
Useful To Me Not Useful To Me | |
ROI25per
Master |
02-Nov-2007 14:27
|
x 0
x 0 Alert Admin |
Abbott Suffers as J&J Clot Woes, Stent Review Nears (Update2)
By Michelle Fay Cortez Nov. 1 (Bloomberg) -- Abbott Laboratories is likely to show regulators that its new heart stent can open clogged arteries better than devices already on the market. Doctors and investors may not be impressed. Research released last week showed that Xience prevented 50 percent more deaths, heart attacks and repeat procedures than Boston Scientific Corp.'s Taxus, the best-selling stent in the U.S. The study failed to show Xience had fewer complications than Taxus or Johnson & Johnson's Cypher, products whose sales plunged 40 percent this year after being linked to lethal clots. Xience won't dominate the $2 billion U.S. stent market unless Abbott can prove it is safe for patients, doctors say. Fifteen of 19 analysts surveyed by Bloomberg rate Abbott a buy, betting Xience will get a positive review at a U.S. regulatory meeting Nov. 29. Some investors say the lack of safety evidence beyond one year of use may limit the device's popularity even if regulators recommend approval. ``Xience continues to show strong efficacy, but not a clean safety profile,'' said Matthew Dodds, a Citigroup analyst with the sole ``sell'' rating on Abbott, in a note to clients. Five cases of blood clots among Xience patients and the lack of long- term data ``are troubling,'' he wrote. `Apprehension' Abbott, which plans to build a medical-device business around Xience, has risen 5.6 percent in the past two weeks since the one-year data showing the device's superiority was presented at a science meeting. The Abbott Park, Illinois-based company fell 50 cents to $54.12 at 4:10 p.m. in New York Stock Exchange composite trading and has gained 14 percent in the past year. The stock may drop to $48 a share if the U.S. Food and Drug Administration asks for more safety data or if doctors balk at using the device until results of larger patient studies are released next year, said Lawrence Keusch, an analyst at Goldman, Sachs & Co., in a note to clients. Keusch, based in New York, raised his rating on Abbott on Oct. 24 to ``buy,'' saying the stock already reflects concern over a possible FDA delay. ``There is clearly apprehension about the need for longer- term follow up,'' said Keusch. He said he expects Xience to capture 24 percent of the U.S. market and $430 million in 2008 sales when the device wins approval. Abbott obtained Xience when it purchased Guidant Corp.'s stent business for $4.1 billion in April 2006. The product is a drug-eluting, or drug-coated, stent that keep clogged arteries from re-closing longer than so-called bare-metal versions. Abbott is seeking to grab business from Taxus and Cypher, the leading drug-coated devices and the only ones sold in the U.S. `Very Confident' ``We've very confident about the data that we have to present to the panel,'' said Karin Bauer Aranaz, an Abbott spokeswoman. ``People have raised questions, but the fact is Xience is the only drug-eluting stent that has been submitted for approval that shows superiority over another drug-eluting stent. That is a first.'' The company will have to share the business with Natick, Massachusetts-based Boston Scientific, which sells a version of Xience under the name Promus. Boston Scientific buys the device from Abbott and pays a 40 percent royalty on sales. By the time a panel of outside advisers meets later this month, Abbott will have two years of safety information on 200 to 300 patients, she said. More Data The U.S. regulatory agency typically wants data on 2,000 patients to uncover rare, catastrophic events, Andrew Farb, an FDA staff member who reviews drug-coated stents, said in an interview. There is flexibility with how long patients need to be followed and what the agency's expert reviewers will decide is enough assurance of safety, he said. ``We always want more data,'' Farb said. ``When we have something that's rare and late, it's a challenge to find. But if we say we want a four-year study, we won't have an answer for four years.'' Many investors say Xience ultimately will be a blockbuster, even if the Rockville, Maryland-based FDA wants more data. Timing is the key issue. ``The FDA may want to take a more conservative approach and make sure there isn't an issue that emerges after you pass a certain point in time,'' said David Heupel, a Minneapolis-based fund manager with Thrivent Financial for Lutherans. ``The sooner the approval the better, but a delay doesn't change anyone's expectations of this being a best in class stent and taking a very significant share of the market when it is fully available.'' `Cautious Approach' Thrivent manages $60 billion in assets, including 2.6 million Abbott shares as of June 30. The stock will have a ``highly favorable'' reaction if Xience gets a full approval from the FDA advisory committee, Heupel said in a telephone interview. If there is a delay, the shares may suffer a bit, though that won't be a surprise to anyone who has paid attention to the issue, he said. Cardiologists who insert stents into arteries have traditionally been swift to adopt new technologies, said Deepak Bhatt, a doctor at the Cleveland Clinic, in Ohio. While that gets medical advances to patients quickly, doctors may be more conservative as a result of the clot complications tied to Taxus and New Brunswick, New Jersey-based J&J's Cypher, he said. ``A more measured, cautious approach is not a bad thing,'' he said in a telephone interview. ``I wouldn't be surprised if that sort of a pattern emerges in the U.S., where doctors aren't quite as quick to jump on board with a new technology as they have been in the past.'' As a result, some cardiologists may wait for longer term safety studies before selecting Xience over its competitors. ``The key thing for Xience is we need to see more long term safety data,'' said Ajay Kirtane, assistant professor of clinical medicine at Columbia University in New York. To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net Last Updated: November 1, 2007 16:38 EDT |
Useful To Me Not Useful To Me | |
cwwan1
Member |
02-Nov-2007 11:59
|
x 0
x 0 Alert Admin |
CHIOOOOOOOOONG AHHHHHHH!!!! |
Useful To Me Not Useful To Me | |
cwwan1
Member |
02-Nov-2007 11:58
|
x 0
x 0 Alert Admin |
I think more good news coming out next week before the quarterly result! Chiong ah! |
Useful To Me Not Useful To Me | |
poppy_toyz
Member |
02-Nov-2007 11:42
|
x 1
x 0 Alert Admin |
Mr Bengster..... End Oct still no CE...So next expected date is mid Nov lor? Got inside information that CE cert is on the way via A380? |
Useful To Me Not Useful To Me | |
b52bomber
Member |
02-Nov-2007 11:41
|
x 0
x 0 Alert Admin |
Warrant Expires At 12 Noon.. 18 minutes from now ... tick! tock! tick! tock! Biosensor can super cheong after that! |
Useful To Me Not Useful To Me | |
AK_Francis
Supreme |
02-Nov-2007 11:38
Yells: "Happy go lucky, cheers." |
x 1
x 0 Alert Admin |
After lunch too late already. Wants kopi $ Cheong Now!!! |
Useful To Me Not Useful To Me |